Who owns NewAmsterdam Pharma Co N.V.?
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Institutional ownership of NAMSW from SEC Form 13F filings across 9 reporting managers. All positions are from one synchronized reporting period — 2026-06-30 books, filed up to 45 days after quarter end — so every row is comparable.
As of the 2026-06-30 reporting period, 9 institutions disclosed 1.3M shares of NewAmsterdam Pharma Co N.V. worth $28.1M — about 1.1% of shares outstanding; the largest disclosed holder is Frazier Life Sciences Management, L.P.. Source: SEC Form 13F filings, parsed by EvidInvest.
9
13F holders
$28.1M
value, 2026 filers
1.1%
of shares outstanding (1.3M sh)
0
new positions (2026 filers)
Top institutional holders
ordered by shares owned · positions as of 2026-06-30 · % of fund = share of the manager's own book · % of co. = share of NAMSW's shares outstanding
| # | Manager | Shares | Value | % of fund | % of co. | Δ shares QoQ |
|---|---|---|---|---|---|---|
| 1 | Frazier Life Sciences Management, L.P. | 500,333 | $10.7M | 0.2% | 0.4% | 0.0% |
| 2 | RA CAPITAL MANAGEMENT, L.P. | 333,333 | $7.1M | 0.1% | 0.3% | 0.0% |
| 3 | Affinity Asset Advisors, LLC | 245,000 | $5.3M | 0.2% | 0.2% | 0.0% |
| 4 | Bain Capital Life Sciences Investors, LLC | 99,999 | $2.1M | 0.1% | 0.1% | 0.0% |
| 5 | DEERFIELD MANAGEMENT COMPANY, L.P. | 92,787 | $2.0M | 0.0% | 0.1% | 0.0% |
| 6 | ARISTEIA CAPITAL, L.L.C. | 15,708 | $343,377 | 0.0% | 0% | 0.0% |
| 7 | WOLVERINE ASSET MANAGEMENT LLC | 14,925 | $318,947 | 0.0% | 0% | +601.7% |
| 8 | Vestcor Inc | 6,666 | $143,000 | 0.0% | 0% | 0.0% |
| 9 | UBS Group AG | 443 | $8,523 | 0.0% | 0% | +11.9% |
Source: SEC Form 13F-HR filings (institutional managers over $100M in US-listed positions). 13Fs disclose long positions only, up to 45 days after quarter end; each manager's latest filed quarter is shown per row and dollar values are the manager's filed marks. Aggregates labeled "2026 filers" count only managers whose latest book is a 2026 quarter. Related: valuation · options positioning · supply chain. Research, not investment advice.